SCHEMBL18283967

SCHEMBL18283967

CCOC(=O)c1nnc(SC)nc1Nc1ccc(C(C)C)cc1

nearest known ligand 0.51

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ SYK P43405 2/20 0.51
▸ MAPT P10636 5/20 0.48
▸ LMNA P02545 2/20 0.48
▸ MEN1 O00255 5/20 0.45
▸ KMT2A Q03164 5/20 0.45
▸ MAPK1 P28482 3/20 0.45
▸ TSHR P16473 2/20 0.45
▸ HTT P42858 1/20 0.43
▸ EGFR P00533 1/20 0.40
▸ KDR P35968 1/20 0.40
▸ NPSR1 Q6W5P4 2/20 0.40
▸ RXFP1 Q9HBX9 1/20 0.40
▸ SMN1; SMN2 Q16637 3/20 0.39
▸ ALDH1A1 P00352 1/20 0.39
▸ GAA P10253 1/20 0.39
▸ NPY1R P25929 1/20 0.39
▸ NPY2R P49146 1/20 0.39
▸ TDP1 Q9NUW8 1/20 0.39
▸ GPR55 Q9Y2T6 1/20 0.39
▸ ILK Q13418 1/20 0.39

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL18283767 0.89 SYK (0.53) SYKMAPTLMNAMEN1KMT2A
SCHEMBL29557846 0.86 ILK (0.53) SYKMAPTLMNAMEN1KMT2A
SCHEMBL28717580 0.86 ILK (0.53) SYKMAPTLMNAMEN1KMT2A
SCHEMBL18283748 0.82 RAB9A (0.41) SYKMAPTLMNAMEN1KMT2A
SCHEMBL23081167 0.81 SYK (0.48) SYKMAPTLMNAMEN1KMT2A
SCHEMBL15910803 0.77 ALOX5 (0.51) SYKMAPTLMNAMEN1KMT2A
SCHEMBL18283801 0.77 JAK3 (0.49) SYKMAPTLMNAEGFR
SCHEMBL15395508 0.77 ALDH1A1 (0.43) SYKMAPTLMNAMEN1KMT2A
SCHEMBL15910735 0.74 EGFR (0.44) SYKMAPTLMNAMEN1KMT2A
SCHEMBL15910710 0.74 SYK (0.46) SYKMAPTLMNAMEN1KMT2A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20210070748-A1 INHIBITORS OF BRUTONS TYROSINE KINASE PHARMACYCLICS LLC (US) 2021-03-11 — — US disclosed
US-20210070748-A1 INHIBITORS OF BRUTONS TYROSINE KINASE PHARMACYCLICS LLC (US) 2021-03-11 — — US disclosed
US-20180305348-A1 INHIBITORS OF BRUTONS TYROSINE KINASE PHARMACYCLICS LLC 2018-10-25 — — US disclosed
EP-3310776-A2 INHIBITORS OF BRUTON'S TYROSINE KINASE Pharmacyclics LLC (US) 2018-04-25 — — EP disclosed
WO-2016196776-A2 INHIBITORS OF BRUTON'S TYROSINE KINASE PHARMACYCLICS LLC. (US) 2016-12-08 — — WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20210070748-A1 INHIBITORS OF BRUTONS TYROSINE KINASE BTK, LYN, LCK SYK 4/4885MAPT 4203/4885LMNA 4022/4885
US-20180305348-A1 INHIBITORS OF BRUTONS TYROSINE KINASE BTK, LYN, LCK SYK 4/4885MAPT 4203/4885LMNA 4022/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback